Results 51 to 60 of about 8,366 (155)

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM

Infection and Drug Resistance, 2023
Junyang Kuai,1 Yawei Zhang,1 Binghuai Lu,2 Hongbin Chen,1 Yulin Zhang,2 Henan Li,1 Yuanyuan Wang,3 Qi Wang,1 Hui Wang,1 Xiaojuan Wang1 1Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, People’s Republic of China ...
Kuai J, Zhang Y, Lu B, Chen H, Zhang Y, Li H, Wang Y, Wang Q, Wang H, Wang X   +9 more
doaj  

Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient

IDCases, 2019
Ceftazidime–avibactam is a combination agent consisting of the β-lactamase inhibitor avibactam and the broad-spectrum cephalosporin ceftazidime. There are no published case reports or studies evaluating the use of CAZ-AVI in pediatric critically ill ...
Maria Vargas, Antonio Riccardo Buonomo, Pasquale Buonanno, Carmine Iacovazzo, Giuseppe Servillo   +4 more
doaj   +1 more source

A Study on Ceftazidime/Avibactam and Aztreonam Synergy Among Aztreonam-resistant Metallo-β-lactamase Producing Enterobacterales in a Tertiary Care Hospital

Mediterranean Journal of Infection, Microbes and Antimicrobials
Introduction: Global detection of bacteria harboring metallo-β-lactamase (MBL) genes has increased at an alarming rate. However, there is no concurrent increase in available antibiotics for treatment, which has turned these infections into a public ...
Adelyn D’SOUZA, Rachana SHETTY, Asha Pai KB   +2 more
doaj   +1 more source

In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase–producing Klebsiella pneumoniae

Antimicrobial Resistance and Infection Control, 2018
Background In recent years, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) infections has increased rapidly. Since the CRE strain is usually resistant to most of antimicrobial agents, patients with this infection are often accompanied by ...
Wenxia Zhang, Yan Guo, Jiayin Li, Yiyuan Zhang, Yang Yang, Dong Dong, Demei Zhu, Ping He, Fupin Hu   +8 more
doaj   +1 more source

Ceftazidime-avibactam susceptibility against Escherichia coli and Klebsiella pneumoniae

Iranian Journal of Microbiology
Background and Objectives: Carbapenem-resistant Enterobacteriaceae (CRE) infections are extremely difficult to treat and have a high fatality rate. The study's primary goal was to determine the rate of ceftazidime-avibactam susceptibility using disc diffusion and E-Test, as well as to evaluate the agreement between the two methods.
Arun Sachu, Alice David
openaire   +3 more sources

Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales.

PLoS ONE
NDM-producing carbapenem-resistant bacterial infections became a challenge for clinicians. Combination therapy of aztreonam and ceftazidime-avibactam is a prudent choice for these infections.
Salman Khan, Arghya Das, Deepali Vashisth, Anwita Mishra, Ashima Jain Vidyarthi, Raghav Gupta, Nazneen Nahar Begam, Babita Kataria, Sushma Bhatnagar   +8 more
doaj   +1 more source

Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study

Current Medicine Research and Practice
Background: The ceftazidime-avibactam combination is able to inhibit ESBLs, AmpCs and Class A carbapenemases and has been recommended for the treatment of complicated UTIs and ventilator-associated bacterial pneumonia.
Reena Rajan, A V Raghavendra Rao, Mathavi Suresh Kumar   +2 more
doaj   +1 more source

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

Infection and Drug Resistance, 2018
Stan D Atkin,1 Shadaan Abid,1 Michael Foster,1 Moumita Bose,1 Ashley Keller,1 Rita Hollaway,2 Helio S Sader,3 David E Greenberg,1,4 James D Finklea,1 Mariana Castanheira,3 Raksha Jain1,4 1Department of Internal Medicine, University of Texas Southwestern ...
Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M, Jain R   +10 more
doaj  

Experience with ceftazidime–avibactam treatment in a tertiary care center in Saudi Arabia

Journal of Infection and Public Health, 2018
Introduction: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide.
Abdullah Algwizani, Mohammad Alzunitan, Ahmad Alharbi, Abdulrahman Alsaedy, Sameera Aljohani, Bassam Alalwan, Jawaher Gramish, Adel Alothman   +7 more
doaj   +1 more source

Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.

Journal of global antimicrobial resistance, 2021
Clinical experience with ceftazidime-avibactam (CAZ-AVI) for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections is not well evaluated. The aim of this study was to assess its efficacy in a single-centre cohort of patients infected with CR-KP.We conducted a retrospective observational study of consecutive patients treated for
Jie, Gu, Jie, Xu, Ting-Ting, Zuo, Yan-Bin, Chen   +3 more
openaire   +1 more source